Idiopathic Inflammatory Myopathies Clinical Trials

29 recruitingLast updated: June 18, 2026

There are 29 actively recruiting idiopathic inflammatory myopathies clinical trials across 24 countries. Studies span Phase 1, Early Phase 1, Phase 2, Not Applicable, Phase 4. Top locations include Iowa City, Iowa, United States, Paris, France, Brest, France. Updated daily from ClinicalTrials.gov.


Idiopathic Inflammatory Myopathies Trials at a Glance

29 actively recruiting trials for idiopathic inflammatory myopathies are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Iowa City, Paris, and Brest. Lead sponsors running idiopathic inflammatory myopathies studies include Tongji Hospital, AstraZeneca, and University Hospital, Brest.

Browse idiopathic inflammatory myopathies trials by phase

Treatments under study

About Idiopathic Inflammatory Myopathies Clinical Trials

Looking for clinical trials for Idiopathic Inflammatory Myopathies? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Idiopathic Inflammatory Myopathies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Idiopathic Inflammatory Myopathies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

PericarditisRheumatoid ArthritisSarcoidosis+10 more
Assistance Publique - Hôpitaux de Paris5,000 enrolled1 locationNCT07077304
Recruiting
Phase 2

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals123 enrolled68 locationsNCT06665256
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Nkarta, Inc.240 enrolled17 locationsNCT06733935
Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled37 locationsNCT06916806
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled52 locationsNCT06991114
Recruiting
Phase 1

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

HealthyIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Xencor, Inc.60 enrolled1 locationNCT07284797
Recruiting
Phase 2

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Behcet's DiseaseIdiopathic Inflammatory MyopathiesIgG4-related Disease
UMC Utrecht60 enrolled6 locationsNCT06285539
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting

Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies

Idiopathic Inflammatory Myopathies (IIMs)
Peking University People's Hospital10 enrolled1 locationNCT07564271
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Early Phase 1

MTS109 in Patients With Refractory Autoimmune Diseases

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)+2 more
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Early Phase 1

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

SLE - Systemic Lupus ErythematosusSSc-Systemic SclerosisIIM- Idiopathic Inflammatory Myopathies
CytoCares Inc6 enrolled1 locationNCT07193810
Recruiting
Early Phase 1

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

Sjogren's SyndromeAutoimmune DiseasesIdiopathic Inflammatory Myopathies+3 more
Nanjing Bioheng Biotech Co., Ltd.20 enrolled1 locationNCT06548607
Recruiting
Phase 1

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

Systemic Lupus Erythematosus (SLE)Idiopathic Inflammatory Myopathies(IIM)
Nanjing Legend Biotech Co.38 enrolled5 locationsNCT07331272
Recruiting
Early Phase 1

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Idiopathic Inflammatory MyopathiesSporadic Inclusion Body Myositis (sIBM)
Austin Neuromuscular Center10 enrolled2 locationsNCT06479863
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

ANCA Associated Vasculitis (AAV)SLE - Systemic Lupus ErythematosusSSc-Systemic Sclerosis+3 more
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07315087
Recruiting
Phase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting
Early Phase 1

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Immune Thrombocytopenia (ITP)Idiopathic Inflammatory Myopathies(IIM)
Shanghai Cell Therapy Group Co.,Ltd20 enrolled1 locationNCT07174843
Recruiting
Phase 1Phase 2

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Myasthenia GravisNMO Spectrum DisorderChronic Inflammatory Demyelinating Polyradiculoneuropathy+1 more
Tianjin Medical University General Hospital27 enrolled1 locationNCT07022197